Drugs / IDE397
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07277413 | Mar 2026 → Apr 2028 expected | biliary tract cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma +7 | IDEAYA Biosciences | Recruiting | No outcome recorded |
| Phase 1 | NCT04794699 | Apr 2021 → Jan 2027 expected | cancer | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05975073 | Aug 2023 → Feb 2026 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE397 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05975073 ↗ |
| Action | Inhibit | “IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).” NCT04794699 ↗ |
| Modality | Small molecule | “IDE397 is a small molecule inhibitor” NCT04794699 ↗ |
| Route | Oral | “IDE397 dosed orally” NCT04794699 ↗ |
| Target | MAT2A | “inhibitor of methionine adenosyltransferase 2 alpha (MAT2A)” NCT04794699 ↗ |